Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).

doi:10.1080/13543776.2021.1841167

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).

Expert opinion on therapeutic patents - 1 Feb 2021

Dockerill Milly, Gregson Clare, O' Donovan Daniel H

Abstract excerpt

INTRODUCTION: PRC2 is a histone methyltransferase complex associated with several cancer types. Tazemetostat was recently approved as the first inhibitor targeting the catalytic subunit EZH2 and several other EZH2 inhibitors are now under clinical evaluation. Beyond EZH2, researchers have also explored other approaches including PRC2 activators, dual agents inhibiting both EZH1 and EZH2, allosteric inhibitors...

Topics

Animals
Antineoplastic Agents
Benzamides
Biphenyl Compounds
Drug Resistance, Neoplasm
Enhancer of Zeste Homolog 2 Protein
Humans
Indoles
Molecular Targeted Therapy
Morpholines
Mutation
Neoplasms
Patents as Topic
Polycomb Repressive Complex 2
Pyridones

Source

Open in PubMed

Identifiers

PMID: 33103538
DOI: 10.1080/13543776.2021.1841167

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics